AL
Therapeutic Areas
PMV Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| rezatapopt (PC14586) | Advanced Solid Tumors with p53 Y220C mutation | Phase 1/2 |
| rezatapopt + pembrolizumab | Advanced Solid Tumors with p53 Y220C mutation | Phase 1/2 |
| rezatapopt + azacitidine | Relapsed/Refractory AML/MDS with p53 Y220C mutation | Investigator-Initiated Trial |
| Undisclosed Program | Solid Tumors (other p53 mutations) | Discovery |